ArticleJournal of medicine and life2022
The role of epithelial membrane antigen (EMA) overexpression in the prognosis of prostatic adenocarcinoma.
Article in Journal of medicine and life, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 2 citations in OpenAlex.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prostatic adenocarcinoma is the second-most common cancer in men and the fifth most common cause of cancer death. Its incidence increases with age; 75% of patients are 65 years and older. The aim of the study was to assess epithelial membrane antigen (EMA) expression in prostatic adenocarcinoma as a poor prognostic marker and its correlation to some pathological parameters. The formalin-fixed, paraffin-surrounded tissue blocks were retrospectively collected from 40 men diagnosed with prostate carcinoma. All cases were collected from Al Hilla Teaching Hospital and some private labs between October 2018 - November 2020, with ages ranging from 30-89 years. Statistical analysis was done using SPSS 22, frequency and percentage were used for categorical data, and Chi-square was used to evaluate connotation between variables. P-value ≤0.05 was significant. The blocks were sectioned for EMA immunohistochemical staining using monoclonal mouse anti-human EMA protein. EMA protein overexpression was detected in 75% (n=30/40) of prostatic adenocarcinoma cases. EMA expression showed no correlation with the patient's age (P=0.09) and a positive correlation with the cancer grade (P=0.003). In prostatic adenocarcinoma patients, EMA could be seen as a potential prognostic predictor for disease progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.